Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Therapeutic Index01:13

Therapeutic Index

7.8K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

619
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
619

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NMR resonance assignments (¹H, ¹³C, ¹⁵N) of jararacin (rJarc), a disintegrin from Bothrops jararaca.

Biomolecular NMR assignments·2026
Same author

A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.

ACS central science·2026
Same author

BmooMPα-I ameliorates aortic fibrosis and hypertrophy in 2K1C hypertensive rats by reducing matrix metalloproteinase-2 activity.

Toxicon : official journal of the International Society on Toxinology·2026
Same author

Structural Basis of Serine Protease Inhibition by Antibodies from Biased Fab Phage-Display Libraries.

bioRxiv : the preprint server for biology·2026
Same author

Structure-guided design of a targeted autoantibody degrader for neurologic disease.

bioRxiv : the preprint server for biology·2026
Same author

Coupling high-throughput protease enzymology with viral replication reveals biochemical constraints of viral fitness.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Apr 14, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.9K

Ecotin: Exploring a feasible antithrombotic profile.

Luciana Serrão Wermelinger1, Flávia Serra Frattani1, Tatiana Correa Carneiro-Lobo2

  • 1Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia/CCS, Universidade Federal do Rio de Janeiro, Rio do Janeiro, RJ, Brazil; Instituto de Bioquímica Médica Leopoldo de Meis/CCS, Universidade Federal do Rio de Janeiro, Rio do Janeiro, RJ, Brazil.

International Journal of Biological Macromolecules
|April 18, 2015
PubMed
Summary
This summary is machine-generated.

Ecotin proteins from Escherichia coli show potent antithrombotic effects. Ecotin-RR, a variant, demonstrated superior thrombin inhibition and increased survival in thrombosis models without causing bleeding.

Keywords:
EcotinFactor Xa inhibitorThrombin inhibitor

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Related Experiment Videos

Last Updated: Apr 14, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.9K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Ecotin, a protein from Escherichia coli, inhibits serine proteases.
  • Ecotin and its variants are being explored for potential antithrombotic therapies.
  • Understanding the antithrombotic mechanisms and efficacy of ecotin variants is crucial.

Purpose of the Study:

  • To evaluate the antithrombotic potential of wild-type ecotin (ecotin-WT) and a double-mutant variant (ecotin-RR).
  • To compare the efficacy of ecotin-WT and ecotin-RR in preventing thrombus formation in vivo.
  • To assess the safety profile, specifically bleeding time, associated with ecotin administration.

Main Methods:

  • In vitro analysis of ecotin activity using coagulation tests.
  • In vivo assessment of antithrombotic activity in rat venous thrombosis and mouse pulmonary thromboembolism models.
  • Evaluation of bleeding time in a rat tail-transection model.

Main Results:

  • Ecotin-RR exhibited stronger inhibition of thrombin compared to ecotin-WT.
  • Both ecotin-WT and ecotin-RR demonstrated anticoagulation activity and reduced thrombus formation.
  • Ecotin-RR significantly improved survival rates in the pulmonary thromboembolism model.
  • No significant increase in bleeding time was observed for either ecotin-WT or ecotin-RR.

Conclusions:

  • Ecotin-WT and ecotin-RR possess potent antithrombotic effects without inducing bleeding.
  • Ecotin-RR shows enhanced efficacy and survival benefits in thrombosis models.
  • These ecotin variants represent promising scaffolds for developing novel anticoagulation therapeutics.